logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme Gains Approval From Brazil For Monoclonal Antibody Lemtrada

Genzyme Corp., a biotechnology company and an unit of Sanofi (SNY), Friday said ANVISA, Brazil's national health surveillance agency, has approved Lemtrada for the treatment of patients with relapsing forms of multiple sclerosis to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

While Mexico, Canada, Australia and EU have approved Lemtrada, FDA has rejected the compound, a decision Genzyme intends to appeal in the future.

The development of the compound included two randomized Phase 3 studies, as well as an ongoing study. The first study, CARE-MS I, compared treatment using Lemtrada with high-dose subcutaneous interferon beta-1a (Rebif) in patients with RRMS who had active disease or were new to treatment. The second study, CARE-MS II, involved patients who had relapsed while on prior therapy.

In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, said the company. The company also said that in CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada versus interferon beta-1a.

The side-effects of Lemtrada include infusion-associated reactions, infections (upper respiratory tract and urinary tract), lymphopenia and leukopenia. Autoimmune conditions and serious infections can occur in patients receiving Lemtrada.

The first course of Lemtrada is administered through IV on five consecutive days, and the second course is administered on three consecutive days, 12 months later.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Discount retailer Family Dollar Stores Inc., which is being acquired by rival Dollar Tree Inc., said Wednesday after the markets closed that its third quarter profit fell slightly from last year, due mainly to a higher effective tax rate. The company's quarterly earnings per share, excluding items, also came in below analysts' expectations. Most of the major automakers, except General Motors Co. (GM), Wednesday reported improved sales results for June, as strong sales of trucks and SUVs continued to help offset weak car sales. Nonetheless, GM's June U.S. sales dropped 3 percent to 259,353 units from 267,461 units last year. The drop... Media and entertainment giant Walt Disney Co. said Tuesday that Christine McCarthy, the company's Treasurer for the past 15 years, will succeed James Rasulo as Chief Financial Officer.
comments powered by Disqus
Follow RTT